Montréal, Quebec, Canada Pharmascience appeared to be the Corporate Investor, which was created in 1983. The main department of described Corporate Investor is located in the Montru00e9al. The company was established in North America in Canada.
The fund has exact preference in a number of founders of portfolio startups. Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund. For fund there is a match between the country of its foundation and the country of its the most frequent investments - Canada. Among the most popular fund investment industries, there are Medical, Life Science. Among the most popular portfolio startups of the fund, we may highlight Edesa Biotech, RDD Pharma.
Opposing the other organizations, this Pharmascience works on 4 percentage points more the average amount of lead investments. The top amount of exits for fund were in 2019. The fund is constantly included in less than 2 deals per year. Considering the real fund results, this Corporate Investor is 13 percentage points more often commits exit comparing to other organizations. Deals in the range of 10 - 50 millions dollars are the general things for fund. The top activity for fund was in 2017.
The usual cause for the fund is to invest in rounds with 2-3 partakers. The meaningful sponsors for the fund in investment in the same round are Signet Healthcare Partners, OrbiMed, Lumira Ventures.
Related Funds
| Fund Name | Location |
| BaseCamp Ventures | Moorestown, New Jersey, United States |
| Calculus Capital | England, London, United Kingdom |
| Ferguson Ventures | Newport News, United States, Virginia |
| ICD-PS | Jeddah, Makkah, Saudi Arabia |
| Nanjing Zhongyiren Investment | China, Jiangsu, Nanjing |
| What If Ventures | Frisco, Texas, United States |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
RDD Pharma | $9M | 16 Nov 2017 | Israel, North District, Israel | ||
Edesa Biotech | $7M | 20 Sep 2017 | Markham, Ontario, Canada |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
RDD Pharma | $9M | 16 Nov 2017 | Israel, North District, Israel | ||
Edesa Biotech | $7M | 20 Sep 2017 | Markham, Ontario, Canada |
